AUTL250516C2500
- 0.02
- 0.000.00%
Autolus Therapeutics Newsroom
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
William Blair Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics: Promising Developments in Lupus Nephritis Drive Buy Rating
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
Autolus Therapeutics Analyst Ratings
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $10
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics Is Maintained at Overweight by Wells Fargo
Autolus Therapeutics Analyst Ratings
Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $6
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $6 to $10
Autolus Therapeutics (AUTL) Gets a Buy From Truist Financial
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Wells Fargo Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $8
Positive Buy Rating for Autolus Therapeutics Driven by Aucatzyl's Promising Launch and Strategic Growth Prospects
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10